CytomX Therapeutics Inc. (CTMX)
NASDAQ: CTMXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
CTMX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $442.55M
- EPS (TTM)
- -$0.51
- Dividend yield
- None
- 52-week range
- 1.87 – 8.21
- Day range
- 1.97 – 2.16
- Volume / Avg
- 4.87M / 4.27M
- Beta
- —
- Shares outstanding
- 218.00M
52-week range
CTMX stock today
On Nov 20, CTMX ended the session at $2.03, shedding $0.02 (0.98%), versus the S&P 500's 3.70% decline. At this level, CTMX sits near the bottom of its 52-week range of $1.87 to $8.21: 75.3% below the high, set on Mar 16, 2026 and 8.6% above the low. CTMX is down 52.3% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 47.7%.
CytomX Therapeutics has posted a net loss over the last twelve months (EPS of -$0.51), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About CytomX Therapeutics
Company profileCytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Sean A. McCarthy DPHIL
- Headquarters
- South San Francisco, CA
- Employees
- 69
- IPO year
- 2015
- Website
- cytomx.com
Financial highlights
Full financialsIn fiscal 2025, CytomX Therapeutics generated $76.2 million in revenue, down 44.8% from fiscal 2024, its first annual decline since 2021. CytomX Therapeutics reported a net loss of $17.4 million, compared with net income of $31.9 million a year earlier. Operating margin was -29.3%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $76.20M | $138.10M | $101.21M | $53.16M | $37.31M |
| Growth | -44.82% | +36.45% | +90.38% | +42.48% | -45.47% |
| Net income | $-17.37M | $31.87M | $-569.00K | $-99.32M | $-115.87M |
| EPS (diluted) | $-0.15 | $0.38 | $-0.01 | $-1.51 | $-1.81 |
Analyst forecast
ForecastConsensus (8 analysts)
strong_buy
Avg. price target
$12.38+509.85%
- Strong buy 3
- Buy 5
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 5, 2026
- EPS actual vs est.
- $-0.09 vs $-0.09
- Surprise
- 0.00%
CTMX news
All CTMX news- Regeneron Wins EC Clearance for Libtayo Dosing FlexibilityNasdaqREGN, SNY, CTMX
- CytomX Earns $5 Million Milestone Payment As Regeneron Cancer Drug Collaboration Advances; Stock UpNasdaqCTMX, HEI.A
- CytomX Therapeutics Announces Milestone Achievement in Strategic Collaboration with Regeneron in the Field of Conditionally Activated BispecificsGlobeNewswire
- CytomX Therapeutics Announces Q3 2026 Financial Results and Provides Business UpdateNasdaq
- CytomX (CTMX) Q3 2026 Earnings Call TranscriptNasdaq
- CytomX Therapeutics Announces Q3 2026 Financial Results and Provides Business UpdateGlobeNewswire
- Qiagen (QGEN) Surpasses Q3 Earnings and Revenue EstimatesNasdaqQGEN, CTMX
- CytomX Therapeutics to Report Third Quarter 2026 Financial Results on November 5, 2026GlobeNewswire
CytomX Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| KMDAKamada Ltd. | 7.74 | -1.15% | $446.85M | vs CTMX |
| DMACDiaMedica Therapeutics Inc. | 8.25 | +2.87% | $445.15M | vs CTMX |
| AMRNAmarin Corporation plc | 10.57 | -6.13% | $444.39M | vs CTMX |
| LYELLyell Immunopharma Inc. | 13.80 | +1.62% | $441.82M | vs CTMX |
| CAPRCapricor Therapeutics Inc. | 7.59 | +0.80% | $441.30M | vs CTMX |
| STTKShattuck Labs Inc. | 4.46 | -1.98% | $454.22M | vs CTMX |
| ASMBAssembly Biosciences Inc. | 22.19 | -1.38% | $454.39M | vs CTMX |
| NGNENeurogene Inc. | 22.15 | -3.40% | $458.53M | vs CTMX |
Indexes, lists and sector
CytomX Therapeutics stock FAQ
What is CytomX Therapeutics's stock price today?
CTMX last traded at $2.03 as of Nov 20, 4:00 PM EST, down 0.98% on the day. Prices are delayed at least 15 minutes.
Who is CytomX Therapeutics's CEO?
Dr. Sean A. McCarthy DPHIL is the chief executive officer of CytomX Therapeutics Inc., which has about 69 employees.
What is the CTMX 52-week high?
The 52-week high for CTMX is $8.21 and the 52-week low is $1.87. The stock is currently 75.3% below its high.